Matching-Adjusted Indirect Comparison of Long-Term Efficacy and Safety Outcomes for Calcipotriol Plus Betamethasone Dipropionate Foam Versus Halobetasol Proprionate Plus Tazarotene Lotion in the Treatment of Plaque Psoriasis

被引：0
|
作者：
David N. Adam
Marie Y. Jablonski Bernasconi
Henrik Thoning
Jashin J. Wu
机构：
[1] University of Toronto,Division of Dermatology, Temerty Department of Medicine
[2] CCA Medical Research,Department of Dermatology
[3] Probity Medical Research,undefined
[4] Leo Pharma,undefined
[5] University of Miami Miller School of Medicine,undefined
来源：
Dermatology and Therapy | 2022年 / 12卷
关键词：
Betamethasone dipropionate; Calcipotriol; Foam; Halobetasol propionate; Psoriasis; Tazarotene;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2589 / 2600
页数：11
相关论文
共 37 条
  • [21] Cost per PASI-75 responder of calcipotriol plus betamethasone dipropionate cutaneous foam versus nonbiologic systemic therapies for the treatment of plaque psoriasis in seven European countries
    Balak, Deepak M. W.
    Carrascosa, Jose-Manuel
    Gregoriou, Stamatis
    Calzavara-Pinton, Piergiacomo
    Bewley, Anthony
    Antunes, Joana
    Nyeland, Martin E.
    Viola, Marta G.
    Sawyer, Laura M.
    Becla, Lidia
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2021, 32 (07) : 701 - 708
  • [22] A matching-adjusted indirect comparison of centanafadine versus lisdexamfetamine, methylphenidate and atomoxetine in adults with attention-deficit / hyperactivity disorder: long-term safety and efficacy
    Schein, Jeff
    Cloutier, Martin
    Gauthier-Loiselle, Marjolaine
    Catillon, Maryaline
    Xu, Chunyi
    Qu, Alice
    Lee, Francesca
    Childress, Ann
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2024, 13 (09)
  • [23] Comparative Efficacy of Ibrutinib Versus Obinutuzumab plus Chlorambucil in First-Line Treatment of Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison
    Van Sanden, Suzy
    Baculea, Simona
    Diels, Joris
    Cote, Sarah
    ADVANCES IN THERAPY, 2017, 34 (07) : 1650 - 1661
  • [24] Long-term safety and efficacy of a fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis: phase 3 open-label study
    Lebwohl, M. G.
    Stein Gold, L.
    Papp, K.
    Han, G.
    Pariser, D. M.
    Lin, T.
    Harris, S.
    Jacobson, A.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (05) : 1152 - 1160
  • [25] Updated Results from a Matching-Adjusted Indirect Comparison of Efficacy Outcomes of Isatuximab Plus Carfilzomib and Dexamethasone Versus Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma
    Richter, Joshua
    Lin, Peggy L.
    Garcia-Horton, Viviana
    Guyot, Patricia
    Zhou, Zheng-Yi
    Sievert, Mark
    BLOOD, 2023, 142
  • [26] Updated Results from a Matching-Adjusted Indirect Comparison of Efficacy Outcomes for Isatuximab Plus Pomalidomide and Dexamethasone Versus Daratumumab Plus Pomalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma
    Leleu, Xavier
    Delea, Thomas
    Guyot, Patricia
    Moynahan, Aaron
    Singh, Erin
    Tekle, Christina
    Lin, Peggy L.
    BLOOD, 2023, 142
  • [27] A MATCHING-ADJUSTED INDIRECT COMPARISON OF CENTANAFADINE VS LISDEXAMFETAMINE, METHYLPHENIDATE, AND ATOMOXETINE IN ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER: LONG-TERM SAFETY AND EFFICACY OUTCOMES
    Schein, J.
    Cloutier, M.
    Gauthier-Loiselle, M.
    Catillon, M.
    Xu, C.
    Qu, A.
    Lee, F.
    Childress, A.
    VALUE IN HEALTH, 2024, 27 (06) : S52 - S52
  • [28] Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis
    Rand, Kim
    Ramos-Goni, Juan Manuel
    Akmaz, Bulent
    Sole-Feu, Laia
    Armario-Hita, Jose-Carlos
    DERMATOLOGY AND THERAPY, 2024, 14 (01) : 169 - 182
  • [29] Reply: Re: Wu JJ, Hansen JB, Patel DS, et al. Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-adjusted indirect comparative analysis. J Med Econ. 2020;23(6):641-649
    Wu, Jashin J.
    Hansen, Jes B.
    Patel, Dharm S.
    Nyholm, Nanna
    Veverka, Karen A.
    Swensen, Andrine R.
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (12) : 1501 - 1502
  • [30] Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis
    Kim Rand
    Juan Manuel Ramos-Goñi
    Bülent Akmaz
    Laia Solé-Feu
    José-Carlos Armario-Hita
    Dermatology and Therapy, 2024, 14 : 169 - 182
1234